Does Aimovig Reduce Chronic Migraine Frequency?
Aimovig (erenumab) is FDA-approved for preventing migraines in adults, including those with chronic migraines (15 or more headache days per month). Clinical trials show it reduces monthly migraine days by 50% or more in about half of patients with chronic migraines. In the Phase 3 LIBERTY trial, patients averaged 8.7 fewer migraine days per month after 12 weeks at 140 mg doses, compared to 7.5 with 70 mg.[1] Real-world data from registries like the AIMOVIG Pregnancy Registry and patient surveys confirm similar reductions, with many reporting 6-10 fewer headache days monthly.[2]
How Quickly Does Aimovig Start Working?
Most patients notice fewer migraines within the first month, with peak effects by 2-3 months. In trials, 40-50% achieved at least a 50% reduction in migraine days by week 4, stabilizing thereafter. Some respond slower, up to 3 months, due to individual factors like migraine severity or CGRP receptor sensitivity.[1][3]
Who Responds Best to Aimovig?
Patients with chronic migraines and high baseline frequency (15+ days/month) see the largest absolute reductions. Those with medication-overuse headache or prior failures on other preventives (like topiramate) often benefit most. Non-responders (about 30-40%) may lack CGRP pathway involvement or have comorbidities like anxiety.[3] Aimovig works regardless of aura presence.
What If Aimovig Doesn't Reduce My Migraines Enough?
Switching doses (70 mg to 140 mg monthly) helps 20-30% of partial responders. Combining with Botox or gepants (like ubrogepant for acute attacks) boosts efficacy in refractory cases, per observational studies. Discontinuation rates are low (10-15% yearly) due to loss of effect.[2][4]
Common Side Effects and Risks for Chronic Migraine Patients
Injection-site reactions occur in 45% (pain, redness), usually mild and fading. Constipation affects 10-20%, managed with laxatives. Rare risks include hypertension (1-2%) and hypersensitivity. No increased stroke or heart attack signals in long-term data up to 5 years. Pregnancy category not established; use contraception if planning.[1][5]
How Does Aimovig Compare to Emgality or Nurtec?
| Drug | Target | Dosing | Avg. Monthly Reduction (Chronic Migraine Trials) | Constipation Risk |
|------|--------|--------|-------------------------------------------------|-------------------|
| Aimovig (erenumab) | CGRP receptor | 70-140 mg monthly subQ | 8.7 days | 10-20% |
| Emgality (galcanezumab) | CGRP ligand | 240 mg loading, 120 mg monthly subQ | 7.8 days | 2-5% |
| Nurtec ODT (rimegepant) | CGRP receptor | 75 mg as-needed (acute + preventive) | 4-6 days (preventive) | <5% |
Aimovig edges out in high-frequency cases but has higher constipation. Cost is similar (~$700/month pre-insurance).[3][6]
When Does Aimovig's Patent Expire?
Core patents expire in 2027-2030 in the US, with extensions possible to 2035 via pediatric exclusivity. Amgen holds 15+ patents; no biosimilars approved yet. Challenges from Teva and others are ongoing.[7]
[1] FDA Aimovig Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761032s000lbl.pdf
[2] American Headache Society Registry Data: https://headachejournal.onlinelibrary.wiley.com/doi/full/10.1111/head.14327
[3] NEJM LIBERTY Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1706445
[4] Cephalalgia Real-World Study: https://journals.sagepub.com/doi/10.1177/03331024211010646
[5] Aimovig 5-Year Safety Data: https://n.neurology.org/content/96/15/e2040
[6] DrugPatentWatch.com (Aimovig patents): https://www.drugpatentwatch.com/p/tradename/AIMOVIG
[7] DrugPatentWatch.com (expiration details): https://www.drugpatentwatch.com/p/tradename/AIMOVIG/patent